SpaceX's Dragon capsule docked onto the ISS and will return to Earth in February. Photo via SpaceX

The two astronauts stuck at the International Space Station since June welcomed their new ride home with Sunday’s arrival of a SpaceX capsule.

SpaceX launched the rescue mission on Saturday with a downsized crew of two astronauts and two empty seats reserved for Butch Wilmore and Suni Williams, who will return next year. The Dragon capsule docked in darkness as the two craft soared 265 miles (426 kilometers) above Botswana.

NASA switched Wilmore and Williams to SpaceX following concerns over the safety of their Boeing Starliner capsule. It was the first Starliner test flight with a crew, and NASA decided the thruster failures and helium leaks that cropped up after liftoff were too serious and poorly understood to risk the test pilots’ return. So Starliner returned to Earth empty earlier this month.

The Dragon carrying NASA’s Nick Hague and the Russian Space Agency’s Alexander Gorbunov will remain at the space station until February, turning what should have been a weeklong trip for Wilmore and Williams into a mission lasting more than eight months.

Two NASA astronauts were pulled from the mission to make room for Wilmore and Williams on the return leg.

“I just want to say welcome to our new compadres,” Williams, the space station commander, said once Hague and Gorbunov floated inside and were embraced by the nine astronauts awaiting them.

Hague said it was a smooth flight up. “Coming through the hatch and seeing all the smiles, and as much as I've laughed and cried in the last 10 minutes, I know it's going to be an amazing expedition," he said.

NASA likes to replace its station crews every six months or so. SpaceX has provided the taxi service since the company’s first astronaut flight in 2020. NASA also hired Boeing for ferry flights after the space shuttles were retired, but flawed software and other Starliner issues led to years of delays and more than $1 billion in repairs.

Starliner inspections are underway at NASA’s Kennedy Space Center, with post-flight reviews of data set to begin this week.

“We’re a long way from saying, ‘Hey, we’re writing off Boeing,’” NASA’s associate administrator Jim Free said at a pre-launch briefing.

The arrival of two fresh astronauts means the four who have been up there since March can now return to Earth in their own SpaceX capsule in just over a week, bringing the station's crew size back down to the normal seven. Their stay was extended a month because of the Starliner turmoil.

Although Saturday’s liftoff went well, SpaceX said the rocket’s spent upper stage ended up outside its targeted impact zone in the Pacific because of a bad engine firing. The company has halted all Falcon launches until it figures out what went wrong.was extended a month because of the Starliner turmoil.

After almost three months, the decision finally came down from NASA’s highest ranks on Saturday. Photo via Vanessa Wyche/LinkedIn

NASA decides to keep 2 astronauts in space until February, nixes return on troubled Boeing capsule

game plan set

NASA decided Saturday it’s too risky to bring two astronauts back to Earth in Boeing’s troubled new capsule, and they'll have to wait until next year for a ride home with SpaceX. What should have been a weeklong test flight for the pair will now last more than eight months.

The seasoned pilots have been stuck at the International Space Station since the beginning of June. A cascade of vexing thruster failures and helium leaks in the new capsule marred their trip to the space station, and they ended up in a holding pattern as engineers conducted tests and debated what to do about the flight back.

After almost three months, the decision finally came down from NASA’s highest ranks on Saturday. Butch Wilmore and Suni Williams will come back in a SpaceX capsule in February. Their empty Starliner capsule will undock in early September and attempt to return on autopilot with a touchdown in the New Mexico desert.

"We are grateful to Butch and Suni for taking on new roles as International Space Station crew members and their families for supporting them in this change to mission plan. Butch and Suni will do good science, technology and STEM engagements on ISS and the entire NASA family will continue to support them during their increment," NASA's Johnson Space Center Director Vanessa Wyche wrote on LinkedIn. "I am personally proud of all of the people who support our human spaceflight endeavors all across the globe. Together, we ensure the safe exploration of space."

As Starliner’s test pilots, the pair should have overseen this critical last leg of the journey.

“A test flight by nature is neither safe nor routine,” said NASA Administrator Bill Nelson. The decision "is a result of a commitment to safety.”

Nelson said lessons learned from NASA's two space shuttle accidents played a role. This time, he noted, open dialogue was encouraged rather than crushed.

“This has not been an easy decision, but it is absolutely the right one,” added Jim Free, NASA's associate administrator.

It was a blow to Boeing, adding to the safety concerns plaguing the company on its airplane side. Boeing had counted on Starliner’s first crew trip to revive the troubled spacecraft program after years of delays and ballooning costs. The company had insisted Starliner was safe based on all the recent thruster tests both in space and on the ground.

Boeing did not participate in Saturday's news conference by NASA, but released a statement.

“Boeing continues to focus, first and foremost, on the safety of the crew and spacecraft," reads the statement. The company said it is preparing the spacecraft “for a safe and successful return.”

Rand Corp.'s Jan Osburg, a senior engineer who specializes in aerospace and defense, said NASA made the right choice. “But the U.S. is still left with egg on its face due to the Starliner design issues that should have been caught earlier."

Wilmore, 61, and Williams, 58, are both retired Navy captains with previous long-duration spaceflight experience. Before their June 5 launch from Cape Canaveral, Wilmore and Williams said their families bought into the uncertainty and stress of their professional careers decades ago.

During their lone orbital news conference last month, the astronauts said they had trust in the thruster testing being conducted. They had no complaints, they added, and enjoyed pitching in with space station work.

Wilmore's wife, Deanna, said she and their daughters, along with family and friends, “were praying for a safe return on whatever spacecraft that may be." While they are disappointed that he will be away longer, “we know that it's the Lord's plan,” she said via text.

Flight operations director Norm Knight said he talked to the astronauts Saturday and they fully support the decision to postpone their return.

There were few options.

The SpaceX capsule currently parked at the space station is reserved for the four residents who have been there since March. They will return in late September, their routine six-month stay extended a month by the Starliner dilemma. NASA said it would be unsafe to squeeze two more into the capsule, except in an emergency.

The docked Russian Soyuz capsule is even tighter, capable of flying only three — two of them Russians wrapping up a yearlong stint.

So Wilmore and Williams will wait for SpaceX's next taxi flight. It’s due to launch in late September with two astronauts instead of the usual four. NASA is yanking two to make room for Wilmore and Williams on the return flight in late February.

NASA said no serious consideration was given to asking SpaceX for a quick stand-alone rescue. Last year, the Russian Space Agency had to rush up a replacement Soyuz capsule for three men whose original craft was damaged by space junk. The switch pushed their six-month mission to just over a year.

Former Canadian astronaut Chris Hadfield, applauded the decision via X: “Good to err on the side of caution for astronaut lives.” Long missions are “what astronauts work their entire career for. I’d take it in a heartbeat!”

Starliner’s woes began long before its latest flight.

Bad software fouled the first test flight without a crew in 2019, prompting a do-over in 2022. Then parachute and other issues cropped up, including a helium leak in the capsule’s propellant system that nixed a launch attempt in May. The leak eventually was deemed to be isolated and small enough to pose no concern. But more leaks sprouted following liftoff, and five thrusters also failed.

All but one of those small thrusters restarted in flight. But engineers were perplexed by ground testing that showed a thruster seal swelling and obstructing a propellant line. They theorized the seals in orbit may have expanded and then reverted to their normal size. Officials said the results marked the turning point, as their concerns grew.

With all the uncertainty about how the thrusters might perform, “There was too much risk for the crew," Steve Stich, NASA's commercial crew program manager, told reporters.

These 28 thrusters are vital. Besides needed for space station rendezvous, they keep the capsule pointed in the right direction at flight’s end as bigger engines steer the craft out of orbit. Coming in crooked could result in catastrophe.

With the Columbia disaster still fresh in many minds — the shuttle broke apart during reentry in 2003, killing all seven aboard — NASA made an extra effort to embrace open debate over Starliner's return capability.

Despite Saturday's decision, NASA isn’t giving up on Boeing. Nelson said he is “100%” certain that Starliner will fly again.

NASA went into its commercial crew program a decade ago wanting two competing U.S. companies ferrying astronauts in the post-shuttle era. Boeing won the bigger contract: more than $4 billion, compared with SpaceX’s $2.6 billion.

With station supply runs already under its belt, SpaceX aced its first of now nine astronaut flights in 2020, while Boeing got bogged down in design flaws that set the company back more than $1 billion. NASA officials still hold out hope that Starliner’s problems can be corrected in time for another crew flight in another year or so.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totalling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.